Literature DB >> 25070856

Essential role for the lectin pathway in collagen antibody-induced arthritis revealed through use of adenovirus programming complement inhibitor MAp44 expression.

Nirmal K Banda1, Gaurav Mehta2, Troels R Kjaer3, Minoru Takahashi4, Jerome Schaack5, Thomas E Morrison5, Steffen Thiel3, William P Arend2, V Michael Holers1.   

Abstract

Previous studies using mannose-binding lectin (MBL) and complement C4-deficient mice have suggested that the lectin pathway (LP) is not required for the development of inflammatory arthritis in the collagen Ab-induced arthritis (CAIA) model. MBL, ficolins and collectin-11 are key LP pattern recognition molecules that associate with three serine proteases-MASP-1, MASP-2, and MASP-3-and with two MBL-associated proteins designated sMAP and MBL-associated protein of 44kDA (MAp44). Recent studies have shown that MAp44, an alternatively spliced product of the MASP-1/3 gene, is a competitive inhibitor of the binding of the recognition molecules to all three MASPs. In these studies, we examined the effect of treatment of mice with adenovirus (Ad) programmed to express human MAp44 (AdhMAp44) on the development of CAIA. AdhMAp44 and Ad programming GFP (AdGFP) expression were injected i.p. in C57BL/6 wild type mice prior to the induction of CAIA. AdhMAp44 significantly reduced the clinical disease activity (CDA) score by 81% compared with mice injected with AdGFP. Similarly, histopathologic injury scores for inflammation, pannus, cartilage and bone damage, as well as C3 deposition in the cartilage and synovium, were significantly reduced by AdhMAp44 pretreatment. Mice treated with AdmMAp44, programming expression of mouse MAp44, also showed significantly decreased CDA score and histopathologic injury scores. In addition, administration of AdhMAp44 significantly diminished the severity of Ross River virus-induced arthritis, an LP-dependent model. Our study provides conclusive evidence that an intact complement LP is essential to initiate CAIA, and that MAp44 may be an appropriate treatment for inflammatory arthritis.
Copyright © 2014 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25070856      PMCID: PMC4134985          DOI: 10.4049/jimmunol.1400752

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  62 in total

1.  Analyzing real-time PCR data by the comparative C(T) method.

Authors:  Thomas D Schmittgen; Kenneth J Livak
Journal:  Nat Protoc       Date:  2008       Impact factor: 13.491

2.  Initiation of the alternative pathway of murine complement by immune complexes is dependent on N-glycans in IgG antibodies.

Authors:  Nirmal K Banda; Allyson K Wood; Kazue Takahashi; Brandt Levitt; Pauline M Rudd; Louise Royle; Jodie L Abrahams; Gregory L Stahl; V Michael Holers; William P Arend
Journal:  Arthritis Rheum       Date:  2008-10

3.  Complement receptor 3 promotes severe ross river virus-induced disease.

Authors:  Thomas E Morrison; Jason D Simmons; Mark T Heise
Journal:  J Virol       Date:  2008-09-10       Impact factor: 5.103

4.  Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I.

Authors:  Charles G Helmick; David T Felson; Reva C Lawrence; Sherine Gabriel; Rosemarie Hirsch; C Kent Kwoh; Matthew H Liang; Hilal Maradit Kremers; Maureen D Mayes; Peter A Merkel; Stanley R Pillemer; John D Reveille; John H Stone
Journal:  Arthritis Rheum       Date:  2008-01

5.  Complement activation pathways in murine immune complex-induced arthritis and in C3a and C5a generation in vitro.

Authors:  N K Banda; B Levitt; A K Wood; K Takahashi; G L Stahl; V M Holers; W P Arend
Journal:  Clin Exp Immunol       Date:  2009-10-19       Impact factor: 4.330

6.  Mannose-binding lectin (MBL)-associated serine protease (MASP)-1 contributes to activation of the lectin complement pathway.

Authors:  Minoru Takahashi; Daisuke Iwaki; Kazuko Kanno; Yumi Ishida; Jie Xiong; Misao Matsushita; Yuichi Endo; Shigeto Miura; Naoto Ishii; Kazuo Sugamura; Teizo Fujita
Journal:  J Immunol       Date:  2008-05-01       Impact factor: 5.422

7.  Activator-specific requirement of properdin in the initiation and amplification of the alternative pathway complement.

Authors:  Yuko Kimura; Takashi Miwa; Lin Zhou; Wen-Chao Song
Journal:  Blood       Date:  2007-10-04       Impact factor: 22.113

8.  MAp44, a human protein associated with pattern recognition molecules of the complement system and regulating the lectin pathway of complement activation.

Authors:  Søren E Degn; Annette G Hansen; Rudi Steffensen; Christian Jacobsen; Jens C Jensenius; Steffen Thiel
Journal:  J Immunol       Date:  2009-11-16       Impact factor: 5.422

9.  Adenovirus-mediated gene transfer of adiponectin reduces the severity of collagen-induced arthritis in mice.

Authors:  Kosuke Ebina; Kazuya Oshima; Morihiro Matsuda; Atsunori Fukuhara; Kazuhisa Maeda; Shinji Kihara; Jun Hashimoto; Takahiro Ochi; Nirmal K Banda; Hideki Yoshikawa; Iichiro Shimomura
Journal:  Biochem Biophys Res Commun       Date:  2008-11-21       Impact factor: 3.575

10.  Essential role of mannose-binding lectin-associated serine protease-1 in activation of the complement factor D.

Authors:  Minoru Takahashi; Yumi Ishida; Daisuke Iwaki; Kazuko Kanno; Toshiyuki Suzuki; Yuichi Endo; Yoshimi Homma; Teizo Fujita
Journal:  J Exp Med       Date:  2009-12-28       Impact factor: 14.307

View more
  21 in total

Review 1.  Complement: an overview for the clinician.

Authors:  Juan Carlos Varela; Stephen Tomlinson
Journal:  Hematol Oncol Clin North Am       Date:  2015-04-04       Impact factor: 3.722

Review 2.  Viral-derived complement inhibitors: current status and potential role in immunomodulation.

Authors:  Hadi Abou-El-Hassan; Hassan Zaraket
Journal:  Exp Biol Med (Maywood)       Date:  2016-10-26

Review 3.  Targeting mechanisms at sites of complement activation for imaging and therapy.

Authors:  V Michael Holers
Journal:  Immunobiology       Date:  2015-04-30       Impact factor: 3.144

4.  Mannan-Binding Lectin-Associated Serine Protease 1/3 Cleavage of Pro-Factor D into Factor D In Vivo and Attenuation of Collagen Antibody-Induced Arthritis through Their Targeted Inhibition by RNA Interference-Mediated Gene Silencing.

Authors:  Nirmal K Banda; Sumitra Acharya; Robert I Scheinman; Gaurav Mehta; Marilyne Coulombe; Minoru Takahashi; Hideharu Sekine; Steffen Thiel; Teizo Fujita; V Michael Holers
Journal:  J Immunol       Date:  2016-10-05       Impact factor: 5.422

5.  Plasma levels of mannan-binding lectin-associated serine proteases MASP-1 and MASP-2 are elevated in type 1 diabetes and correlate with glycaemic control.

Authors:  L Jenny; R Ajjan; R King; S Thiel; V Schroeder
Journal:  Clin Exp Immunol       Date:  2015-05       Impact factor: 4.330

6.  Combining MAP-1:CD35 or MAP-1:CD55 fusion proteins with pattern-recognition molecules as novel targeted modulators of the complement cascade.

Authors:  Laura Pérez-Alós; Rafael Bayarri-Olmos; Mikkel-Ole Skjoedt; Peter Garred
Journal:  FASEB J       Date:  2019-08-30       Impact factor: 5.191

7.  Evaluation of Targeting Efficiency of Joints with Anticollagen II Antibodies.

Authors:  Laren A Lofchy; Vivian P Vu; Nirmal K Banda; Joseline Ramos Ramirez; Weston J Smith; Geoffrey Gifford; Hanmant Gaikwad; Robert I Scheinman; Dmitri Simberg
Journal:  Mol Pharm       Date:  2019-05-15       Impact factor: 4.939

Review 8.  The complement system as a potential therapeutic target in rheumatic disease.

Authors:  Leendert A Trouw; Matthew C Pickering; Anna M Blom
Journal:  Nat Rev Rheumatol       Date:  2017-08-10       Impact factor: 20.543

9.  Deconstructing the Lectin Pathway in the Pathogenesis of Experimental Inflammatory Arthritis: Essential Role of the Lectin Ficolin B and Mannose-Binding Protein-Associated Serine Protease 2.

Authors:  Nirmal K Banda; Sumitra Acharya; Robert I Scheinman; Gaurav Mehta; Minoru Takahashi; Yuichi Endo; Wuding Zhou; Conrad A Farrar; Steven H Sacks; Teizo Fujita; Hideharu Sekine; V Michael Holers
Journal:  J Immunol       Date:  2017-07-24       Impact factor: 5.422

10.  A New Approach for the Treatment of Arthritis in Mice with a Novel Conjugate of an Anti-C5aR1 Antibody and C5 Small Interfering RNA.

Authors:  Gaurav Mehta; Robert I Scheinman; V Michael Holers; Nirmal K Banda
Journal:  J Immunol       Date:  2015-04-27       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.